Parkinson's Disease
Conditions
Interventions
Experimental group:The experimental group receiving treatment of Levodopa/Carbidopa/Entacapone (LCE)
Control group:The control group receiving treatment of Levodopa/Carbidopa (LC)
Sponsors
Department of Neurology, Dongyang People’s Hospital, Affiliated to Wenzhou Medical University.
Eligibility
Sex/Gender
All
Age
45 Years to 85 Years
Inclusion criteria
Inclusion criteria: ?The study subjects were from patients who met the diagnostic criteria for Parkinson's Disease according to the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria; ? myotonia, postural gait disorder, static tremor, bradykinesia as the main performance; ? Patients with Hoehn-Yahr grading of 3-5 points according to the severity of clinical symptoms; ? Sign informed consent.
Exclusion criteria
Exclusion criteria: ? secondary cerebrovascular disease, encephalitis, craniocerebral trauma and other Parkinson's syndrome; ? There have been serious infections recently; ? Patients with malignant tumor; ? Serious cardiovascular disease, liver and kidney insufficiency; ? Patients with a history of repeated stroke; ? Patients with Parkinson's syndrome; (7) Patients with complex vertebral system injury and abnormal cerebellar function, etc; ? The use of Levodopa/Carbidopa/Entacapone is contraindicated; ? Patients who are participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Motor function, quality of life, cognitive function and neuropsychological function scales scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Peripheral Inflammatory Cytokines; | — |
Countries
China
Contacts
Public ContactDongjuan Xu
Department of Neurology, Dongyang People’s Hospital, Affiliated to Wenzhou Medical University.
Outcome results
None listed